GlassScriptPhysician profile
Seth Thomas Billington
NPI 1306555115
$3,335.30
in general payments reported to CMS, 2019-2025
32 companies · $2,031 in 2025
The $2,031 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $673 · 2024: $632 · 2025: $2,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.61 | 2023-2025 | |
| Pfizer INC. | $409.60 | 2023-2025 | |
| Nevro Corp. | $230.45 | 2023-2024 | Senza |
| Boston Scientific Corporation | $201.24 | 2023 | Wavewriter Alpha Prime 16 |
| Intrinsic Therapeutics | $198.55 | 2023 | Barricaid Acd (Annular Closure Device) |
| Medtronic, INC. | $184.71 | 2024 | Intellis Adaptivestim |
| Genzyme Corporation | $183.26 | 2025 | |
| Saluda Medical Americas, INC. | $100.45 | 2023-2025 | Evoke, Evoke Scs |
| Genentech USA, INC. | $92.01 | 2025 | Ocrevus Zunovo |
| Lilly USA, LLC | $80.93 | 2025 | Kisunla |
| Amneal Pharmaceuticals LLC | $71.58 | 2025 | Crexont |
| Tg Therapeutics, INC. | $64.60 | 2025 | |
| Jazz Pharmaceuticals INC. | $46.92 | 2025 | |
| Janssen Biotech, INC. | $46.72 | 2025 | |
| Tonix Medicines, INC. | $35.92 | 2025 | Zembrace Symtouch |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.70 | 2025 | Symbravo |
| Merz Pharmaceuticals, LLC | $31.81 | 2025 | Xeomin, Inbrija, Ampyra |
| Globus Medical, INC. | $28.87 | 2025 | Senza |
| Sk Life Science, INC. | $28.19 | 2025 | |
| Averitas Pharma INC. | $27.60 | 2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $27.07 | 2025 | Hyqvia |
| Augmedics INC. | $26.51 | 2024 | Xvision |
| Ucb, INC. | $24.93 | 2025 | Rystiggo |
| Novartis Pharmaceuticals Corporation | $22.48 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $22.15 | 2025 | Austedo Xr |
| Eisai INC. | $22.03 | 2025 | |
| Neurocrine Biosciences, INC. | $18.98 | 2025 | |
| Spr Therapeutics, INC | $18.88 | 2024 | Sprint Pns System |
| Theragen, INC. | $18.75 | 2023 | Actastim-S |
| Emd Serono, INC. | $18.53 | 2025 | |
| Argenx US, INC. | $17.99 | 2025 | Vyvgart Hytrulo |
| Si-Bone, INC. | $14.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Billington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.